Adults with relapsed or refractory large B-cell lymphoma after ≥2 lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.
CD19-directed genetically modified autologous T-cell immunotherapy. A patient’s own T cells are reprogrammed with a transgene encoding a chimeric antigen receptor (CAR) to identify and eliminate CD19-expressing malignant and normal cells.
For autologous use only.
A single dose of axicabtagene ciloleucel is administered by IV infusion 2 days after completing lymphodepletion with conditioning chemotherapy.
Dosing of axicabtagene is based on the number of chimeric antigen receptor (CAR)-positive viable T cells.
Target dose is 2 x 106 CAR-positive viable T cells/kg body weight, not to exceed 2 x 108 CAR-positive viable T cells.
See the Certificate of Analysis for the actual number of CAR-positive T cells in the product.
Approval was based on results from the ZUMA-1 study (n=111), an open-label, multicenter trial. Following conditioning treatment (cyclophosphamide and fludarabine) for 3 days, 101 patients received axicabtagene ciloleucel. The ORR in the mITT analysis set of 101 patients was 82% (CR 54%, PR 28%). At a median follow-up of 8.7 months, 44% were in response and 39% were in CR. The median duration of response was 8.2 months overall and not reached for patients who achieved a CR. Median overall survival was not reached; 80% of patients remained alive at 6 months.
Locke FL, et al. CT019 - Primary results from ZUMA-1: a pivotal trial of axicabtagene ciloleucel (axicel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL). American Association for Cancer Research. Available at https://www.abstractsonline.com/pp8/#!/4292/presentation/12336. April 2, 2017; Accessed: November 14, 2017
Medscape © 2018 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Mary L Windle. FDA New Drug and Biologic Approvals -- 2017 Year-in-Review - Medscape - Jan 11, 2018.